What question did this study set out to answer?

The aim is to evaluate current prognostic factors and biomarkers in AL amyloidosis and identify gaps in existing models.

March 6, 2026Blood

Prognostic Factors and Progression Biomarkers in AL Amyloidosis: Mapping Current Knowledge and Critical Gaps

View Full Paper

Ask AI

Bookmark

Authors

This review analyzes prognostic factors and progression biomarkers in AL amyloidosis, indicating critical knowledge gaps.

The aim is to evaluate current prognostic factors and biomarkers in AL amyloidosis and identify gaps in existing models.
Comprehensive review of literature on AL amyloidosis prognostic factors and biomarkers.
Categorization of factors into disease-specific and patient-specific.
Analysis of traditional and emerging biomarkers for prognostic significance.
Daratumumab regimens show a 76% five-year overall survival.
Traditional biomarkers like dFLC are becoming less significant with new therapies.
Emerging dynamic markers and cardiac imaging parameters show potential for better risk stratification.
Highlights the need for validation studies and refinement of prognostic models.

Chakraborty et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark